Combining PSMA-PET and PROMISE to re-define disease stage and risk in prostate cancer – APCCC

Advanced Prostate Cancer Consensus Conference posted the following on LinkedIn:

“Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on The Lancet Oncology.

This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against established clinical nomograms for prostate cancer, focusing on overall survival.

Data from 2,414 patients with prostate cancer from hospitals in Germany were analyzed, with follow-up data linked to mortality records. Using Cox regression models, the researchers developed quantitative and visual PPP nomograms, which were validated both internally and externally.

The PPP nomograms showed superior or comparable predictive accuracy for overall survival compared to traditional risk scores, like STARCAP, EAU, and NCCN, in different stages of prostate cancer. Further validation and refinement are ongoing.”

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Authors: Madeleine J Karpinski, MSc, Johannes Hüsing, PhD, Kevin Claassen, PhD, Lennart Möller, MPH, Hiltraud Kajüter, MSc, Florian Oesterling, MSc, Prof Viktor Grünwald, MD, Prof Lale Umutlu, MD, Prof Jens Kleesiek, PhD, Tugce Telli, MD, Anja Merkel-Jens, MD, Anika Hüsing, PhD, Claudia Kesch, MD, Prof Ken Herrmann, MD, Prof Matthias Eiber, MD, Sebastian Hoberück, MD, Prof Philipp T Meyer, MD PhD, Felix Kind, MD, Prof Kambiz Rahbar, MD, Prof Michael Schäfers, MD, Prof Andreas Stang, MD MPH, Prof Boris A Hadaschik, MD, Prof Wolfgang P Fendler, MD

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn